ZA202212179B - Aptamers for use in the treatment of coronaviridae infections - Google Patents

Aptamers for use in the treatment of coronaviridae infections

Info

Publication number
ZA202212179B
ZA202212179B ZA2022/12179A ZA202212179A ZA202212179B ZA 202212179 B ZA202212179 B ZA 202212179B ZA 2022/12179 A ZA2022/12179 A ZA 2022/12179A ZA 202212179 A ZA202212179 A ZA 202212179A ZA 202212179 B ZA202212179 B ZA 202212179B
Authority
ZA
South Africa
Prior art keywords
coronaviridae
viruses
aptamers
treatment
molecules
Prior art date
Application number
ZA2022/12179A
Other languages
English (en)
Inventor
Haberland Annekathrin
Müller Johannes
Wallukat Gerd
Göttel Peter
Original Assignee
Berlin Cures GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/059328 external-priority patent/WO2021205012A1/en
Application filed by Berlin Cures GmbH filed Critical Berlin Cures GmbH
Publication of ZA202212179B publication Critical patent/ZA202212179B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA2022/12179A 2020-04-09 2022-11-08 Aptamers for use in the treatment of coronaviridae infections ZA202212179B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20168929 2020-04-09
EP20176023 2020-05-22
EP20180781 2020-06-18
EP20204036 2020-10-27
PCT/EP2021/059328 WO2021205012A1 (en) 2020-04-09 2021-04-09 Aptamers for use in the treatment of coronaviridae infections

Publications (1)

Publication Number Publication Date
ZA202212179B true ZA202212179B (en) 2025-03-26

Family

ID=84191962

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/12179A ZA202212179B (en) 2020-04-09 2022-11-08 Aptamers for use in the treatment of coronaviridae infections

Country Status (11)

Country Link
US (1) US12606828B2 (enExample)
EP (1) EP4133083A1 (enExample)
JP (1) JP2023521361A (enExample)
KR (1) KR20220166337A (enExample)
CN (1) CN115768895A (enExample)
AU (1) AU2021252151A1 (enExample)
BR (1) BR112022020439A2 (enExample)
CA (1) CA3175067A1 (enExample)
IL (1) IL297155A (enExample)
MX (1) MX2022012618A (enExample)
ZA (1) ZA202212179B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3007984T3 (en) * 2021-04-09 2025-03-21 Berlin Cures GmbH Aptamers for use in the treatment of coronaviridae infections
KR102937192B1 (ko) * 2023-01-25 2026-03-17 주식회사 리젠시스랩 사스 코로나 바이러스 2 특이적 압타머 및 이의 용도
WO2025146959A1 (ko) * 2024-01-02 2025-07-10 충북대학교 산학협력단 SARSCoV2의 외피 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009508473A (ja) * 2005-08-26 2009-03-05 アーケミツクス・コーポレイシヨン 高親和性でトロンビンに結合するアプタマー
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
KR102596343B1 (ko) * 2016-11-23 2023-10-31 베를린 큐어스 게엠베하 TLR9 활성화의 저해 및/또는 억제에 사용되는 압타머(aptamer)

Also Published As

Publication number Publication date
US12606828B2 (en) 2026-04-21
BR112022020439A2 (pt) 2022-11-29
IL297155A (en) 2022-12-01
JP2023521361A (ja) 2023-05-24
AU2021252151A1 (en) 2022-12-08
CA3175067A1 (en) 2021-10-14
MX2022012618A (es) 2022-11-07
CN115768895A (zh) 2023-03-07
KR20220166337A (ko) 2022-12-16
EP4133083A1 (en) 2023-02-15
US20230140490A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
WO2020198509A3 (en) Modified oligonucleotides with increased stability
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
GEAP202416053A (en) Modified short interfering nucleic acid (sina) molecules and uses thereof
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
MX2022013945A (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos.
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
BR112015018493A2 (pt) Linhagens celulares para produção de vírus e métodos de uso
MX394033B (es) Un Método para Inhibir o Reducir una Infección Viral por Coronavirus
ZA202212136B (en) Anti-bk virus antibody molecules
JP2014500249A5 (enExample)
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
Gu et al. Endothelium‐derived engineered extracellular vesicles protect the pulmonary endothelial barrier in acute lung injury
BR112022020439A2 (pt) Aptâmeros para uso no tratamento de infecções de coronaviridae
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
MX2022014326A (es) Proteinas multiespecificas.
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
ZA202209180B (en) Compositions and methods for treating long covid
WO2019147308A3 (en) Rna nanostructures and methods of making and using rna nanostructures
PH12022552499A1 (en) Technologies for preventing or treating infections
NZ783377A (en) Pegylated novel molecules for agonising tlr2
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
WO2009138146A3 (de) Neue therapeutika für die hepatitis-therapie
BR112022003686A2 (pt) Tratamento de sintomas induzidos pelo ciclo menstrual
PL386175A1 (pl) Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
ZA202309185B (en) Aptamers for use in the treatment of coronaviridae infections